Introduction {#s1}
============

Malaria remains a major public health challenge, with more than 7% of deaths among children under 5 years in the world attributable to the disease ([@bib25]). Many of these cases arise in regions with high universal immunization coverage. In sub-Saharan Africa alone where 80% of malaria cases occur ([@bib57]), district coverage rates are estimated at over 70% for the third dose of diphtheria--tetanus--pertussis (DTP) vaccines and 75% for measles-containing vaccines ([@bib56]).

Several studies have suggested that childhood immunization may confer non-specific health effects beyond targeted diseases, but the impact of standard vaccination and vitamin A supplementation on malaria infection is unclear. In particular, early evidence from murine models indicates that injection with live strains of Bacille Calmette Guerin (BCG) vaccine may confer sterilizing protection against *Plasmodium* infection ([@bib8]). However, this effect seems to depend on several factors including route of administration (intradermal, subcutaneous, intramuscular vs intravenous), type of immunogen used (killed vs live attenuated), vaccine schedule in relation to malaria exposure (before vs after infection), mouse strain, sex, and *Plasmodium* species tested ([@bib8]; [@bib4], [@bib46], [@bib47]; [@bib33], [@bib3]). Conversely, the risk of malaria infection has been thought to increase during downregulation in cellular immunity (including interleukin-12, interferon-gamma, T cells) and T helper (Th) 2 cell upregulation following measles infection and/or immunization ([@bib12]). Epidemiological evidence to support this theory in humans remains unclear ([@bib54]; [@bib40]).

Multiple clinical trials in infants and young children have also identified protective effects from vitamin A supplementation against illness (number and time to first clinical episode, risk of febrile illness, spleen enlargement, and mean parasite density) ([@bib44]; [@bib58]) and death caused by malaria ([@bib14]; [@bib50]; [@bib34]). Vitamin A is thought to act as a regulator of pro-inflammatory response genes (e.g. tumor necrosis factor alpha) and phagocytotic clearance (e.g. cluster of differentiation 36 \[CD36\]) of *Plasmodium falciparum*-infected erythrocytes, by way of its active metabolite, retinoic acid ([@bib42]). Less certain is its impact on malaria infection. While vitamin A did not appear to modulate the risk of parasitemia in a clinical trial study of Ghanaian children ([@bib5]) and Tanzanian children previously hospitalized with pneumonia ([@bib52]), a cluster randomized intervention trial for breastfeeding in Uganda observed a sixfold decrease in the adjusted risk of malaria infection among children receiving vitamin A ([@bib35]). On the other hand, concern has been raised by an apparent increase in levels of parasitemia within mouse models, when combining vitamin A supplements with DTP vaccination; an effect thought to be stronger among female mice ([@bib24]). The underlying mechanisms of these effects are unclear, although it has been theorized that vitamin A may act as adjuvant to DTP, which is postulated to cause detrimental effects ([@bib24]).

Based on this evidence, the purpose of this study was to determine the risk of *Plasmodium* parasitemia and *P. falciparum*-specific antigenemia following vitamin A supplementation and standard vaccination in children under 5 years of age in sub-Saharan Africa.

Results {#s2}
=======

Children\'s characteristics {#s2-1}
---------------------------

Of 20,984 children who presented health cards during survey interviews, 18,413 were eligible for blood screening from which 12,058 provided capillary blood for malaria testing ([Figure 1](#fig1){ref-type="fig"}). From these, 8672 (72%) were tested using both thick blood films and rapid *P. falciparum* histidine rich protein-2 (*Pƒ*HRP-2) tests, 3356 (28%) were tested only with blood films, and 30 (0.2%) were tested with only rapid *P*ƒHRP-2 tests. Among those tested, we identified 3544 (30%) with positive blood films for *Plasmodium* spp. and 3131 (36%) with positive *P*ƒHRP-2 antigenemia. Results from both tests were 87% concordant. Complete confounder information was available for 8390 (70%) subjects who were tested for parasitemia and 6121 (70%) tested for antigenemia. [Table 1](#tbl1){ref-type="table"} shows BCG, DTP, and poliomyelitis vaccines were used most often. Vitamin A was least used. [Supplementary file 3](#SD3-data){ref-type="supplementary-material"} shows that immunization schedules were similar across all countries ([@bib55]). Malaria was most common among subjects from Burkina Faso and least common among those from Rwanda. Although Rwanda had the longest rainy season, they also had the greatest ownership of bed nets, and were least likely to have recently used antimalarials or had a mother who used antimalarials during pregnancy. Although HIV testing was not conducted among children, the mothers of 2540 subjects were tested for HIV. Twenty-four (0.94%) were seropositive, suggesting that the potential for vertical transmission might be low. There were no significant differences in seropositivity across countries.10.7554/eLife.03925.003Figure 1.Flow chart of subjects.**DOI:** [http://dx.doi.org/10.7554/eLife.03925.003](10.7554/eLife.03925.003)10.7554/eLife.03925.004Table 1.Baseline characteristics of 8390 children tested for malaria using blood film, by survey location**DOI:** [http://dx.doi.org/10.7554/eLife.03925.004](10.7554/eLife.03925.004)*Characteristic*Location of surveyOverall (n=8390)Burkina Faso (n=2821)Mozambique (n=2266)Rwanda (n=2085)Senegal (n=1218)Communities surveyed, n5376074903712005(a) Children tested for malaria, n (%) *Parasitemia*2821 (99)2266 (100)2085 (99)1218 (99)8390 (99) Positive result among children tested for parasitemia 1696 (60) 578 (25) 16 (0.8) 22 (1.8) 2312 (28) *Pƒ-HRP-2*2821 (100)na2060 (99)1217 (99)6098 (99)[\*](#tblfn1){ref-type="table-fn"} Positive results among children tested for *Pƒ-HRP-2* 2051 (73)na 35 (1.7) 27 (2.2) 2113 (35)(b) Type of immunization received, n (%) *Bacille Calmette Guerin (BCG)*2799 (99)2004 (96)2050 (100)1160 (98)8013 (98) *Diphtheria--tetanus--pertussis (DTP)*2721 (97)2107 (97)2055 (98)1161 (98)8044 (98) *Measles*2225 (80)1668 (78)1727 (86)830 (73)6450 (80) *Poliomyelitis*2810 (100)2156 (99)2061 (100)1204 (100)8231 (99) *Vitamin A*87 (9.3)1554 (87)351 (72)190 (59)2182 (62)(c) Children\'s characteristics *Age in months, median (IQR)*22 (13--32)20 (13--31)24 (14--36)19 (12--29)22 (13--32) *Girls, n (%)*1347 (48)1151 (51)1020 (49)551 (45)4069 (48) *Primigravidae, n (%)*443 (16)477 (21)432 (21)251 (21)1603 (19) *Low birth weight, n (%)*867 (31)1003 (44)672 (32)536 (44)3078 (37)(d) Malaria-based interventions, n (%) *Child\'s family owns bed net*2160 (77)1528 (67)1983 (95)1040 (85)6711 (80) Child received antimalarial during past week314 (11)117 (5.2)50 (2.4)24 (2.0)505 (6.0) Child\'s house had indoor insecticide spraying22 (0.8)541 (24)na148 (12)711 (8.5)[†](#tblfn2){ref-type="table-fn"} Mother took antimalarial during child\'s gestational period2616 (93)1109 (50)337 (16)1110 (91)5162 (62)(e) Genetic mechanisms of malaria protection, median (IQR) Mean predicted HbS allele frequency0.06 (0.05--0.06)0.03 (0.01--0.03)0.03 (0.03--0.03)0.07 (0.06--0.07)0.04 (0.03--0.06) Median predicted G6PDd allele frequency0.06 (0.05--0.09)0.15 (0.15--0.17)0.04 (0.04--0.05)0.10 (0.09--0.13)0.08 (0.05--0.14)(f) Climate of communities surveyed, median (IQR) *Annual range of enhanced vegetation index (EVI)*0.29 (0.24--0.32)0.33 (0.22--0.40)0.25 (0.20--0.29)0.28 (0.18--0.34)0.28 (0.22--0.33) *Annual mean of EVI for the year*0.22 (0.18--0.25)0.40 (0.32--0.47)0.39 (0.36--0.42)0.18 (0.16--0.20)0.29 (0.20--0.40) *No. of days which EVI above annual mean*136 (120--160)88 (56--128)320 (168--384)208 (184--264)152 (120--200) *No. of days for rainy season (corresponding to first and last day EVI above annual mean)*136 (120--152)128 (72--344)344 (296--352)216 (152--352)168 (120--344)[^1][^2]

Impact of routine immunization on malaria infection {#s2-2}
---------------------------------------------------

[Table 2](#tbl2){ref-type="table"} shows that while BCG vaccination was not associated with *Plasmodium* parasitemia, it was linked to an increased risk of *P*ƒHRP-2 antigenemia. This effect remained after controlling for patient characteristics associated with BCG use in the inverse probability weighted (IPW) model. DTP was associated with a lower risk of *Plasmodium* parasitemia and *P*ƒHRP-2, but only in the weighted models. Measles and poliomyelitis vaccination were not associated with malaria antigenemia or parasitemia. [Figure 2A](#fig2){ref-type="fig"} shows that the strength of associations between BCG and antigenemia were greater if children were vaccinated during the wet season, among younger children and the more time passed since vaccination.10.7554/eLife.03925.005Table 2.Relative risk of malaria infection after standard vaccination and vitamin A supplementation among children 6--59 months of age**DOI:** [http://dx.doi.org/10.7554/eLife.03925.005](10.7554/eLife.03925.005)Type of immunizationNo. of children vaccinated/total tested (%)No. of children with positive blood test (%)Unadjusted RRAdjusted RR (95% CI)[‡](#tblfn5){ref-type="table-fn"},[§](#tblfn6){ref-type="table-fn"}No vaccineVaccineUnweightedWeighted (IPW)(a) *Plasmodium* species (parasitemia)[\*](#tblfn3){ref-type="table-fn"} Bacille Calmette Guerin (BCG)8013/8140 (98)41 (32)2227 (28)0.811.25 (0.81--1.91)1.24 (0.76--2.05) Diphtheria--tetanus--pertussis (DTP)8044/8235 (98)83 (44)2202 (27)0.490.88 (0.64--1.20)0.06 (0.01--0.47) Measles6450/8069 (80)473 (29)1784 (28)0.931.11 (0.96--1.29)1.01 (0.20--5.19) Poliomyelitis8231/8272 (99)14 (34)2278 (28)0.740.80 (0.37--1.73)0.74 (0.27--2.01) Vitamin A supplement2182/3523 (62)596 (44)438 (20)0.310.46 (0.39--0.54)0.43 (0.36--0.52)(b) *Plasmodium falciparum* (antigenemia) Bacille Calmette Guerin (BCG)6006/6047 (99)9 (22)2102 (35)1.914.06 (2.00--8.28)3.52 (1.66--7.48) Diphtheria--tetanus--pertussis (DTP)5933/6054 (98)59 (49)2049 (35)0.551.34 (0.88--2.02)0.06 (0.01--0.38) Measles4776/5937 (80)410 (35)1679 (35)0.991.15 (0.97--1.38)0.68 (0.15--3.12) Poliomyelitis6.072/6084 (99)5 (42)2111 (35)0.751.39 (0.55--3.49)0.93 (0.37--2.35) Vitamin A supplement629/1749 (36)621 (56)75 (12)0.100.23 (0.17--0.29)0.22 (0.16--0.29)[^3][^4][^5][^6][^7]10.7554/eLife.03925.006Figure 2.Adjusted relative risk of malaria infection according to different features of vitamin A supplementation and BCG vaccination([@bib25]; [@bib57]). (**A**) Adjusted for the following factors: age, gender, wealth index score, mother\'s highest level of education, malaria treatment during previous week, ownership of bed net, proportion of household members under 5 years using bed net during previous night, indoor household insecticide spraying, mother\'s access to antenatal care during last pregnancy, mother\'s knowledge regarding vertical HIV transmission, malaria transmission season, and type of community setting (urban vs rural). (**B**) Covariates 'Age at vaccination' and 'Time since vaccination' treated as continuous terms when testing for effect modification in the model. (**C**) Seasonality only available for children vaccinated in 2010 or 2011 calendar year.**DOI:** [http://dx.doi.org/10.7554/eLife.03925.006](10.7554/eLife.03925.006)

Impact of vitamin A supplementation on malaria infection {#s2-3}
--------------------------------------------------------

Vitamin A supplementation appeared protective against *Plasmodium* parasitemia and *P*ƒHRP-2 antigenemia ([Table 2](#tbl2){ref-type="table"}). These effects remained after weighting. [Figure 2](#fig2){ref-type="fig"} illustrates that the association between vitamin A and *Plasmodium* parasitemia was not impacted by season, age or time since supplementation. However, for antigenemia, vitamin A was moderately more protective in older children (p~trend~\<0.001), the more time passed since supplementation (p~trend~\<0.001) or if supplementation was given during the wet season (p~trend~=0.04). [Table 3](#tbl3){ref-type="table"} reveals that associations between vitamin A and parasitemia were stronger among children 36--59 months of age or if their mother took an antimalarial during pregnancy. The relation with *P*ƒHRP-2 antigenemia was stronger if children had a negative malaria blood film, were 36--59 months of age, primigravidae, or had not taken an antimalarial recently. Vitamin A was more protective against *P*ƒHRP-2 among children with low birth weight but was less protective against parasitemia. The association between vitamin A and *P*ƒHRP-2 was stronger among children tested during the dry season or who lived in communities with a longer rainy season, and in communities with a lower annual mean for enhanced vegetation index (EVI). Associations between vitamin A and parasitemia were stronger among communities with a higher mean predicted sickle cell hemoglobin (HbS) allele frequency or median predicted glucose-6-phosphate dehydrogenase deficiency (G6PDd) allele frequency. We had insufficient data to identify cross-interactions between vaccines and vitamin A using an adjusted model, but in unadjusted models we found no significant interactions between vaccination and vitamin A supplementation.10.7554/eLife.03925.007Table 3.Modifiers of the association between vitamin A supplementation and malaria infection among children 6--59 months of age**DOI:** [http://dx.doi.org/10.7554/eLife.03925.007](10.7554/eLife.03925.007)Characteristics at blood testingLevel in the model*Plasmodium* species (parasitemia)[\*](#tblfn7){ref-type="table-fn"}*Plasmodium falciparum* (antigenemia)[†](#tblfn8){ref-type="table-fn"}No. of children with positive blood film (%)Unadjusted RRAdjusted model^3^No vitamin AVitamin ARR (95% CI)p Value (interaction term)Adjusted RR[‡](#tblfn9){ref-type="table-fn"} (95%CI)p Value (interaction term)(a) Individual levelChildren\'s characteristics Age at malaria screening6--35 Months484 (43)344 (20)0.330.46 (0.38--0.55)\<0.01[\#](#tblfn11){ref-type="table-fn"}0.26 (0.20--0.34)\<0.01[\#](#tblfn11){ref-type="table-fn"}36--59 Months112 (54)94 (21)0.230.34 (0.25--0.47)0.09 (0.05--0.14) GenderGirl274 (44)226 (21)0.340.54 (0.44--0.67)0.290.23 (0.16--0.32)0.99Boy322 (45)212 (19)0.290.40 (0.32--0.49)0.23 (0.17--0.30) Pregnancy order of childPrimigravidae522 (47)366 (21)0.300.45 (0.38--0.53)0.270.20 (0.15--0.27)0.04Multigravidae74 (31)72 (15)0.410.51 (0.39--0.66)0.33 (0.22--0.48) Birth weight2500 mg or greater332 (42)204 (15)0.240.39 (0.32--0.48)0.010.27 (0.20--0.36)0.02Less than 2500 mg264 (48)234 (28)0.430.53 (0.43--0.66)0.13 (0.09--0.18) Treatment for intestinal worms during past 6 monthsNot received554 (46)212 (25)0.390.50 (0.40--0.61)0.080.38 (0.28--0.52)0.07Received37 (30)221 (17)0.460.66 (0.52--0.86)0.15 (0.11--0.21)Malaria-based interventions Malaria treatment during previous weekNot received550 (44)404 (19)0.310.44 (0.37--0.52)0.240.20 (0.16--0.27)0.02Received46 (49)34 (33)0.510.88 (0.62--1.26)1.01 (0.60--1.68) Mother took antimalarial during child\'s gestational periodNo102 (28)226 (22)0.690.78 (0.59--1.03)\<0.0010.38 (0.19--0.74)0.05Yes491 (50)210 (19)0.230.36 (0.30--0.45)0.20 (0.16--0.27) Family owns bed netDoes not own bed net141 (47)123 (22)0.320.43 (0.34--0.56)0.420.20 (0.15--0.26)0.70Owns bed net455 (44)315 (41)0.310.48 (0.40--0.58)0.24 (0.18--0.32)(B) Community level (primary sampling unit) Type of settingRural518 (50)370 (25)0.350.46 (0.39--0.56)0.950.22 (0.17--0.30)0.91Urban78 (26)68 (9.4)0.290.34 (0.22--0.51)0.22 (0.12--0.40)Genetic mechanisms of malaria protection Mean predicted HbS allele frequency[§](#tblfn10){ref-type="table-fn"}Less than 2.5%14 (20)104 (14)0.780.78 (0.32--1.91)\<0.01[\#](#tblfn11){ref-type="table-fn"}-0.26[\#](#tblfn11){ref-type="table-fn"}2.5--4.9%181 (41)269 (25)1.490.95 (0.64--1.42)0.96 (0.24--3.91)5% or greater401 (48)65 (18)0.210.31 (0.17--0.56)0.17 (0.08--0.39) Median predicted G6PDd allele frequency[§](#tblfn10){ref-type="table-fn"}Less than 7.5%336 (47)47 (11)0.045.42 (2.01--14.6)\<0.001[\#](#tblfn11){ref-type="table-fn"}1.43 (0.28--7.21)0.02[\#](#tblfn11){ref-type="table-fn"}7.5--14.9%194 (43)128 (18)0.800.89 (0.52--1.50)0.41 (0.12--1.34)15% or greater66 (40)263 (25)0.650.74 (0.46--1.19)-Climate of communities surveyed Season of malaria transmissionDry season198 (42)220 (19)0.320.40 (0.31--0.52)0.450.06 (0.03--0.13)\<0.001Wet season398 (46)218 (22)0.320.53 (0.42--0.66)0.39 (0.28--0.53) Length of rainy seasonLess than 120 days168 (49)151 (21)0.270.43 (0.31--0.61)\<0.001[\#](#tblfn11){ref-type="table-fn"}0.28 (0.15--0.50)0.03[\#](#tblfn11){ref-type="table-fn"}120--179 Days334 (56)105 (26)0.270.45 (0.33--0.62)0.22 (0.15--0.31)180 Days or more94 (23)182 (17)0.700.77 (0.56--1.05)0.21 (0.10--0.43) Length of time enhanced vegetation index above annual meanLess than 120 days105 (42)220 (21)0.380.50 (0.37--0.69)0.18[\#](#tblfn11){ref-type="table-fn"}0.37 (0.09--1.60)0.84[\#](#tblfn11){ref-type="table-fn"}120--179 Days486 (52)206 (27)0.340.52 (0.42--0.66)0.33 (0.24--0.45)180 Days or more5 (3.3)12 (3.2)0.970.43 (0.12--1.62)0.66 (0.16--2.85) Range of enhanced vegetation index per yearLess than 0.2046 (25)41 (7.9)0.260.38 (0.22--0.63)0.18[\#](#tblfn11){ref-type="table-fn"}0.24 (0.13--0.47)0.13[\#](#tblfn11){ref-type="table-fn"}0.20--0.29247 (44)105 (17)0.250.48 (0.36--0.64)0.36 (0.25--0.53)0.30 or greater303 (51)292 (28)0.380.48 (0.39--0.61)0.19 (0.13--0.29) Annual mean for enhanced vegetation indexLess than 0.20150 (37)21 (7.2)0.130.17 (0.11--0.28)\<0.01[\#](#tblfn11){ref-type="table-fn"}0.16 (0.10--0.25)0.01[\#](#tblfn11){ref-type="table-fn"}0.20--0.29309 (59)89 (24)0.220.51 (0.37--0.70)0.34 (0.23--0.51)0.30 or greater137 (33)328 (22)0.560.61 (0.46--0.81)0.56 (0.20--1.53)[^8][^9][^10][^11][^12][^13]

Discussion {#s3}
==========

In this large, population-based study within sub-Saharan Africa, vitamin A supplementation was associated with a negative risk of *Plasmodium* parasitemia and *P*ƒHRP-2 antigenemia among children aged 6--59 months. None of the vaccines examined in our study (i.e. BCG, DTP, measles, and poliomyelitis) appeared to be linked with *Plasmodium* parasitemia in unweighted models but we did observe a threefold to fourfold elevated risk of *P*ƒHRP-2 among BCG vaccinated children. Controlling for factors related to the utilization of vaccines, this association remained significant for BCG. Measles vaccination did not appear to be associated with either *Plasmodium* parasitemia or *P*ƒHRP-2 antigenemia suggesting that the vaccine may not incur any long-term differences in the risk of malaria, as previously suggested in the literature.

Vitamin A, DTP and gender {#s3-1}
-------------------------

Our study extends previous randomized clinical trial evidence from Burkina Faso ([@bib58]), Papua New Guinea ([@bib44]), Tanzania ([@bib51]), and Uganda ([@bib35]) showing consistent reductions in malaria-induced morbidity and mortality from vitamin A. Still, it contradicts suggestions that when combined with DTP ([@bib24]), vitamin A may increase the risk of malaria infection. Not only did we identify a protective association between vitamin A and malaria in a study population with high immunization coverage for BCG, DTP, and poliomyelitis, we also found in unadjusted models that DTP did not modify vitamin A\'s association with malaria. We found no indication of an elevated gender effect for either DTP or vitamin A, although the latter seemed to be more protective among children living in communities with higher allele frequencies for X-linked G6PDd. It is unclear how vitamin A could interact with G6PD to influence the risk of malaria infection; the only literature discussion regarding vitamin A and G6PD is limited to animal findings on adipose and lipogenic activities ([@bib19]; [@bib2]). However, G6PDd is independently related to risk reductions in malaria, a driving factor in the high prevalence of G6PDd across Africa ([@bib21]). G6PDd is also expressed more often in boys than girls due to the X-linked nature of the gene ([@bib21]). All of the epidemiological evidence to support the detrimental gender-based effects from vitamin A and DTP on child mortality comes from Guinea Bissau ([@bib1a], [@bib2a]; [@bib15]). Whether relatively mild phenotypic differences between G6PDd alleles could explain such different vaccine effects is not clear.

Placental malaria and vitamin A {#s3-2}
-------------------------------

Differences in the impact of vitamin A on malaria infection by birth weight, and having a mother who used antimalarials during the child\'s gestational period suggests exposure to placental malaria may play a critical role in vitamin A\'s protective effect mechanisms later on in childhood. Published evidence regarding placental malaria, antenatal vitamin supplementation, and infant health are limited. However, [@bib9] have identified a lower level of antibodies involved in placental parasite sequestration and risk reductions in active placental malaria infection at delivery in mothers who received vitamin A supplements during pregnancy. Additional research may be warranted on the impact of vitamin A supplementation in young children with known prenatal exposure to malaria.

BCG and soil-transmitted helminths {#s3-3}
----------------------------------

Results from a previous clinical trial in Guinea Bissau provides no evidence of an association between BCG re-vaccination and malaria parasitemia ([@bib39]). Although the study had a number of design limitations (i.e. did not examine the magnitude of the re-vaccination boosting effect on prior immunity from BCG, was statistically underpowered (potentially causing type I error), and based on passive case detection of malaria at health centers/outpatient clinics), it does suggest that our inconsistent findings between *Plasmodium* parasitemia and *P*ƒHRP-2 antigenemia may be due to another factor. In 2012, the tropical diseases research (TDR) programme reported false positivity caused by schistosomiasis and Chagas in one lot of Paracheck *P*ƒ rapid diagnostics ([@bib57a]). Infection with *Trypanosoma cruzi*, schistosomiasis, and other soil-transmitted helminths is inversely associated with anti-mycobacterial responses due to Th1/Th2 polarization ([@bib28]; [@bib13]; [@bib7]; [@bib10]), and albendazole increases BCG immune reactivity among children infected with schistosomiasis ([@bib10]). Although Chagas is not endemic to the countries we studied ([@bib31]), there is growing evidence that schistosomiasis may be an overlooked, endemic disease among infants and young children in sub-Saharan Africa ([@bib41]).

Strengths, limitations and additional research direction {#s3-4}
--------------------------------------------------------

Our study represents an active population-based surveillance of malaria infection within four countries. The breadth and size of the study population enabled us to evaluate the association between malaria and childhood vaccines/vitamin A despite high vaccination coverage rates within most of the communities surveyed ([@bib12]). Although our models adjusted for factors that could explain study population differences between blood film and antigenemia models, to address this issue further we ran a sensitivity analysis using blood film data including/excluding Mozambique. This analysis showed that when Mozambique data were excluded from blood film analysis, the magnitude of protective vitamin A effects in both blood film and antigenemia models were nearly identical. Blood films and antigenemia readings are used to identify two different outcomes (i.e. blood films test for *Plasmodium* spp. while antigenemia test for one particular type of *Plasmodium* \[*P. falciparum*\])*.* However, due to geography, blood films were likely to be detecting *P. falciparum* due to geography ([@bib17], [@bib18]). This would explain the similar results identified between blood film and antigenemia results when excluding Mozambique data from our analysis. We have chosen to present data in this paper that includes Mozambique because these results provide more conservative estimates of vitamin A effects when using blood films. A number of study limitations should also be considered when reviewing our results.

First, while we used propensity scores to address differences in patient characteristics associated with vaccine uptake, the possibility of residual confounding due to unmeasured factors remains. Moreover, because of the observational nature of our study design, high-quality randomized clinical trials are needed to confirm the efficacy of vitamin A in preventing malaria, particularly among children exposed to placental malaria. This includes further clarification regarding optimal dosages and the time sequence in which vitamin A is administered in relation to other vaccines, as well as more accurate measures with regard to HbS and G6PDd allele frequency. In particular, our study only considered information regarding the last recorded dose of vitamin A supplement rather than a child\'s history of supplementation. Given that vitamin A is fat soluble and can be stored in the liver for long periods of time ([@bib6]; [@bib48]), additional research is needed to examine whether regular supplementation has an impact on increased protection.

Second, although the EVI dataset is advantageous for this research due to its spatial and temporal resolutions, several caveats are associated with EVI that affect its utility as a proxy for seasonal rainfall. Foremost among these concerns is the time lag between rainfall and vegetation response, as dormant vegetation does not immediately become green following the return of seasonal rains ([@bib36]; [@bib11]). This issue will create a temporal offset between EVI and rainfall that may complicate the interpretation of the results of this research. However, this concern will be partially mitigated by a similarly lagged response to rainfall in populations of vector species responsible for spreading *Plasmodium* ([@bib30]; [@bib16]). Another concern when using EVI as a proxy for rainfall relates to non-uniform responses of vegetation to rainfall that reflect long-term moisture conditions (via land cover) rather than seasonal oscillations ([@bib49]). This issue is most apparent when comparing dry season EVI values in grasslands to those in forests, as forests tend to retain more green vegetation (and thus have higher EVI values) even when dry due to deeper root systems, etc. A second aspect of EVI linked to land cover differences is the speed at which vegetation responds to rainfall, as plants in drier ecosystems have evolved to respond more quickly to infrequent rain events ([@bib37]). For this research, differing responses to land cover are accounted for by deriving unique EVI curves for each survey cluster location, thus creating relative metrics based on only localized (i.e. per-cell) EVI values rather than regional summaries that contain responses of multiple land cover types.

Finally, data on children\'s HIV status were not available. Although the possibility of mother-to-child HIV transmission was low in our study (less than 1% of mothers were HIV positive), HIV is an established risk factor for malaria infection ([@bib1]). To address this issue, we adjusted a subgroup of models for maternal HIV status. While the protective association between vitamin A and malaria remained, the low prevalence of maternal HIV in our study population (and hence low statistical power) makes it difficult to rule out potential vitamin A--HIV interactions. Further research is needed to evaluate potential interactions between vitamin A, HIV and malaria infection.

Materials and methods {#s4}
=====================

Study design and data collection {#s4-1}
--------------------------------

Data were extracted from Macro International Demographic and Health Surveys (DHS) ([@bib23]), a database of nationally representative household surveys conducted in low and middle-income countries. We focused on standard DHS surveys carried out since January 2010, which tested children for malaria using blood films (gold standard malaria test) and documented children\'s use of standard vaccines and vitamin A supplements. Malaria indicator surveys were excluded from our study due to the absence of data on childhood immunization. From 20 country surveys with accessible data (last checked 15 January 2014), we identified four surveys that fitted these criteria (i.e. Burkina Faso, Mozambique, Rwanda, and Senegal). All surveys were conducted between May 2010 and November 2011, and used a multistage sampling process, by which study participants were identified from randomly selected households within a primary sampling unit (PSU) (e.g. census enumeration tract). Trained interviewers used standardized questionnaires to collect information from participants during home interviews on a range of issues related to population, health, and nutrition. Geographical waypoints (World Geodetic System 84 datum, latitude, and longitude) were also recorded at the center of each PSU. Eligible subjects for our analysis included children 6--59 months of age who, during survey interviews, provided blood samples for malaria screening and had their history of vaccination and vitamin A supplementation documented based on health records. Each DHS had comprehensive ethical approval and written informed consent was collected for each survey participant (see below). Additional data were extracted from external sources on malaria seasonality and the population prevalence of malaria protective genes using the geographical coordinates of each PSU (n=2604 community waypoints).

### Data on climate conditions for malaria {#s4-1-1}

To estimate seasonality, an EVI dataset was used as it relates to seasonal precipitation, albeit lagged in time, and the emergence of vector mosquito species. This dataset was created from moderate resolution imaging spectroradiometer (MODIS) bidirectional reflectance distribution function (BRDF)-corrected composites (MCD43B4) ([@bib43]), which have a 1 km spatial resolution and a 16-day temporal resolution. By utilizing MODIS data from sensors located on both the Aqua and Terra satellite platforms, the temporal resolution of the final EVI dataset was increased to 8 days, or 46 grids (i.e. rasters or images) per year. The MODIS BRDF data were acquired in tiles from the NASA Reverb site (<http://reverb.echo.nasa.gov/>), 42 of which were required to create each 8-day mosaic of Africa for 2000 through 2012. EVI was then calculated for each mosaic using the equation defined by [@bib22]. Due to cloud cover, which was particularly problematic in forested regions of equatorial west Africa, a cloud-filling algorithm was applied to each EVI grid to create a spatially complete dataset ([@bib5a]). From the gap-filled EVI dataset, values were extracted in R 3.0.0 (R Foundation, Vienna, Austria) for each PSU waypoint for all dates from 2010 and 2011 to create a longitudinal EVI profile for each point. From each profile, we calculated the following indices for both years of the study: i. mean EVI; ii. start of the rainy season corresponding to an EVI above the annual mean; iii. end of the rainy season, corresponding to an EVI below the annual mean occurring after ii; iv. number of days between ii and iii; v. number of days with an EVI above the annual mean; vi. date of the minimum EVI; and vii. date of the maximum EVI.

### Data on genetic mechanisms of malaria protection {#s4-1-2}

Predicted allele frequencies for HbS ([@bib38]) and G6PDd ([@bib20]) were extracted for each PSU waypoint from continuous global predicted surface maps of the worldwide distribution of these genes using ArcGIS 10.1 (Esri, Redlands, CA). These surface maps were generated as part of the Malaria Atlas Project (MAP) ([@bib26]), using Bayesian geostatistical models of prevalence data collected from a systematic review of community-based surveys ([@bib17]). The survey database consisted of both published and unpublished literature ([@bib32]).

Identification of vaccination and vitamin A supplementation history {#s4-2}
-------------------------------------------------------------------

Information regarding children\'s vaccination and vitamin A supplementation history was ascertained from health card data recorded during the survey interview. This included a child\'s date of vaccination using BCG, DTP, measles and polio as well as the number of vaccine doses received (for DTP and polio only). We used these data then to calculate age in months at the moment of vaccination, and time in months since vaccination. Children whose mother/guardian responded in the affirmative to vaccination (e.g. child vaccinated during campaign) but did not provide health cards to document this information were excluded from the analysis. For vitamin A supplementations, data were recorded regarding the date of last dose received and use of the vitamin supplement during the 6 months prior to the survey interview.

Determination of malaria status {#s4-3}
-------------------------------

Primary study outcomes included the microscopic detection of *Plasmodium* spp. to assess parasitemia and the presence of *P*ƒHRP-2 to assess antigenemia. The microscopic presence of *Plasmodium* spp. was determined by reading Giemsa-stained thick blood films. Species of *Plasmodium* spp. were not recorded. Capillary blood was collected during household interviews and tested onsite for malaria antigenemia. *Pƒ*-specific HRP-2 antigens were detected using the rapid diagnostic Paracheck *Pf* (Orchid Biomedical Services, Goa, India) for Burkina Faso and Senegal surveys and first response malaria antigen HRP-2 (Premier Medical Corporation, Daman, India) for the Rwanda survey. Thick blood smears were prepared by trained technicians for all children, and sent for gold standard testing of malaria to the Centre National de Recherche et de Formation sur le Paludisme (Burkina Faso), Centro de Investigações em Saúde de Manhiça (Mozambique), TRAC/Plus Malaria Unit in Kigali (Rwanda) and Department of Parasitology at the Université Cheikh Anta Diop (Senegal). Internal quality control was conducted using standard laboratory protocol and procedures, including having slides randomly read by different laboratory technicians or the chief technician/supervisor for internal quality control measures. External quality control (Mozambique only) included selecting samples by a computerized system developed by ICF Macro and sending them for external quality control testing at the Muraz Center (Bobo-Dioulasso).

Determination of current HIV status among mothers {#s4-4}
-------------------------------------------------

Capillary blood was collected during household interviews from all women aged 15--29 years. Samples were collected on filter paper, dried for 24 hr and then sent for testing to the Centre Regional de Transfusion Sanguine de Ouagadougou (Burkina Faso), National Reference Laboratory (Rwanda) and National Reference Laboratory of Bacteriology and Virology at A Le Dantec Hospital (Senegal). Viral antibodies were detected using the enzyme-linked immunosorbent assay (ELISA)-based assay VironostikaÒ HIV Uni-Form II plus O (Biomériux, Marcy l\'Etoile, France). Positive samples and a portion of negative samples were tested using the ELISA assay EnzygnostÒ Anti-HIV ½ plus (Siemens AG, Erlangen, Germany). Discordant samples were further tested using the Pepti Lav assay (Bio-Rad Laboratories, Hercules, CA) or InnoLia (Burkina Faso and Rwanda). Internal quality control measures (Burkina Faso, Rwanda and Senegal) included using control wells (positive and negative) provided with manufacturer\'s screening kit on each test plate. All positive samples and 10% of randomly selected negative samples were also tested using more than one assay, with discordant samples further tested using a third assay. External quality control measures (Burkina Faso only) consisted of sending all positive samples and 80 randomly selected negative samples to the Center Muraz (Bobo-Dioulasso) for additional HIV testing.

Statistical analysis {#s4-5}
--------------------

Multivariable logistic regression models were used to estimate associations between malaria and childhood vaccination/supplementation. The impact of age at vaccination, time since vaccination, and malaria season on the date of vaccination were also examined. To avoid statistical inference errors in our results due to clustering and stratification from the sampling process, we defined country and PSU as strata, and households as clusters using logistic regression models that accounted for the complex survey data structure. To test for linear trends, covariates were included as continuous terms in the regression model. We adjusted models for continuous variables of age and wealth index score, and categorical variables of gender (boy vs girl), malaria treatment during previous week (yes vs no), ownership of bed net (yes vs no), proportion of household members under 5 years old using bed net during previous night (none, all, some, or no bed net), indoor household insecticide spraying (yes vs no), malaria transmission season (dry vs wet), community setting (urban vs rural), mother\'s highest educational level (none, incomplete primary, complete primary, incomplete secondary, complete secondary, post-secondary), and access to antenatal care during last pregnancy (yes vs no). Complete subject analysis was used. [Supplementary file 1](#SD1-data){ref-type="supplementary-material"} presents children\'s characteristics for missing (excluded) and non-missing (included) groups.

Effect modifiers for each vaccine/vitamin model were identified by individually testing cross-product terms between type of immunization/supplement received and individual-based characteristics including age, gender, pregnancy order of child, birth weight, receipt of antimalarial during previous week, receipt of intestinal worm treatment during previous 6 months, if mother took antimalarial during child\'s gestational period, family owns bed net, or type of community setting; climate-related factors including malaria transmission season at time of immunization, length of rainy season, length of time that EVI was above annual mean, range of EVI per year, or annual mean for EVI; and malaria genetic factors including the predicted allele frequency in a community for HbS (mean estimate) and G6PDd (median estimate). To account for uncertainty in spatial prediction values for HbS and G6PDd, we conducted a sensitivity analysis by excluding from models any prediction value with degrees of uncertainty (i.e. interquartile range) greater than 20%.

### Avoidance of selection bias {#s4-5-1}

Due to the observational nature of the data (not randomized), we controlled for differences in patient characteristics associated with vaccine or vitamin use, by inverse probability weighting of models using the propensity score for receiving a vaccine or vitamin supplement. Predictors of vaccination/supplementation included in propensity score models were: age, gender, low birth weight, presence of radio/television in home, urban versus rural setting, breastfeeding status, wealth index score, as well as mother\'s age, highest education level, antenatal care during last pregnancy, and tetanus status during last pregnancy. Standardized bias measures were used to assess numerical balance in propensity score covariate distributions, before and after IPW weighting ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). Factors with standardized bias values ≤0.25 were considered balanced.

All statistical analyses were completed using SAS v.9.3 (SAS Institute, Cary, NC) and R v.3.0.0 (R Foundation, Vienna, Austria).

Ethical considerations {#s4-6}
----------------------

Prior to enrolling in the survey, the parent/adult responsible for the child had to provide written informed consent to participate, along with additional informed consent for blood sample collection and testing. If a child tested positive during the survey using malaria RDT, their parent/guardian was informed of results and the child was immediately given treatment according to the current treatment guidelines. HIV tests for adults were anonymous, with survey data only being linked to test results after respondent identifiers were deleted from the database. Although HIV test results were not available to study participants, patients were offered cards enabling them to obtain free HIV testing and counselling at Voluntary Testing Centers. The Institutional Review Board of ICF Macro reviewed and approved the MEASURE Demographic and Health Surveys Project Phase III, in compliance with United States (U.S.) Department of Health and Human Services (DHHS) regulation 45 Code of Federal Regulations (CFR) 46 for 'Protection of Human Subjects' research. Protocols for blood specimen collection, HIV and malaria testing were also approved by ICF Macro International Institutional Review Board (IRB) \[all countries\] in compliance with U.S. DHHS regulation 45 CFR 46 for 'Protection of Human Subjects' research, National Ethics Committees \[Burkina Faso, Rwanda and Senegal\] and U.S. Centers for Disease Control \[Rwanda only\]. For Senegal, supervisory visits were also organized by the National Ethics Committee to ensure field compliance with ethical regulations. Geographical waypoints were randomly displaced to ensure confidentiality \[Urban PSU: positional error of 0--2 km; and, Rural PSU: positional error of 0--5 km (99% of clusters), or 0--10 km error (1% of clusters)\]. DHS provided anonymized data to study authors. As a secondary analysis of publically available de-identified data, the study was determined exempt from ethics review by Johns Hopkins Bloomberg School of Public Health IRB Office according to U.S. DHHS regulation 45 CFR 46.102 for non-human subject research.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Vitamin A supplements, routine immunization, and the subsequent risk of malaria among children 6 to 59 months of age" for consideration at *eLife*. Your article has been evaluated by Prabhat Jha (Senior editor), a Reviewing editor, and 4 reviewers.

The following individuals responsible for the peer review of your submission have agreed to reveal their identity: Stephen Tollman (Reviewing editor) and John Pettifor (peer reviewer). Please note that a further three reviewers conducted detailed assessments.

The Reviewing editor and the reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

The study aimed to assess the effects of both vitamin A supplementation and immunization on malaria parasitemia and antigenemia in sub--Saharan children between the ages of 6 and 59 months, in order to verify the findings in experimental animals in which vitamin A supplementation and immunizations have been shown to confer some protection against malaria infection. The authors conclude that BCG vaccination did not influence malaria parasitemia but did increase PƒHRP2 antigenemia, while vitamin A supplementation reduced the prevalence of both parasitemia and antigenemia. The BCG effect on antigenemia was thought to be due to an increase in false positivity due to Chagas disease or *Schistosomiasis*. Due to the low malaria burden in two of the four countries, the study is driven by data from Burkina Faso and Mozambique. If confirmed, the findings are of importance to the many children living in high malaria infection zones---with potential policy impact.

Substantive comments are detailed below. However, the major concern of all reviewers relates to limitations of the DHS dataset, ensuring that comparisons and analyses of the observational work are valid and adequately explained/justified, gaining a better understanding of country--level effects, and concerns about ethical practice in global health survey work.

Major/substantive comments:

1\) The four populations studied differ in malaria burden, climate and vitamin A use. It is unclear whether some of the differences between the blood film and RDT assessments are due to the omission of Mozambique (one of two countries with relatively high parasite prevalence) from the latter. Further, amidst the range of correcting/confounding variables it is not clear how \'country\' as a geopolitical unit was considered.

2\) Because the populations are not the same for blood film and antigenaemia readings, it is hard to interpret the findings from the two analyses (e.g. for vitamin A, where age--and time--dependent trends with antigen are presented but are difficult to explain biologically, unless they reflect host and environmental/social differences between Burkina Faso, which contributes the overwhelming number of malaria antigen cases, and Mozambique). This makes it difficult to single out the take--home message; or have confidence that the antigen findings are generalisable.

3\) Clearly there is value in capitalising on the cross--country comparisons possible from DHS data. But the Methods section could be much clearer on whether children vaccinated were compared with those unvaccinated (and if not, how the groups assessed for protection were selected). Since this is observational rather than trials data, adequate explanation of this design/analysis issue is essential. (High vaccination coverage overall raises the question whether comparing vaccinated against unvaccinated children is valid given possible selection biases.)

4\) Quality of National Data: The authors are silent on country--level quality control activities for malaria diagnosis, especially on the expertise and methods used by those responsible for blood smear readings.

5\) Ethical approval: The authors state that "the study was determined exempt from ethics review by Johns Hopkins Bloomberg School of Public Health". It is not appropriate to have such approval from Johns Hopkins only; an understanding of the ethical status of the work in countries where the data were collected is needed. Furthermore, it would be helpful to know how children who tested malaria positive were managed.

6\) It is mentioned that 20,948 children presented health cards during the survey interviews. It is stated that 12,028 were tested using thick blood films and 8702 using RDTs, but were the tests on each child limited to either thick film examination or RDT or both? If only one, how was concordance determined; and if both, what was the overlap (and please explain how children were accounted for as either thick film (12,028) or RDT (8702) to sum to 20,948)?

Note: numbers in the text and [Tables 1 and 2](#tbl1 tbl2){ref-type="table"} are not all in agreement. Since microscopy is the stated \'gold standard\' it might be clearer if the analysis in [Table 1](#tbl1){ref-type="table"} included only those children with microscopy results.

7\) Please provide information on selection of confounders. And consider:

a\) HIV status and vertical HIV exposure, as these may influence a child\'s immune response to both vaccination and vitamin A supplementation;

b\) Number of doses of each of the immunizations or vitamin A supplements received (it is likely that older children had more immunizations and A supplements than younger). Were immunization schedules and supplementation programmes similar in the four countries?

8\) Third paragraph in the Results section: the authors indicate that vitamin A was more protective the greater the time from the last dose. The last panel of [Figure 2B](#fig2){ref-type="fig"} does not seem to show this, nor does the statement tally with the first paragraph of the Discussion.

9\) Fourth paragraph in the Discussion section: the authors suggest that the increase in antigenemia associated with BCG vaccination might be due to false positivity from other parasitic infections; also that false--positivity has been reported in Paracheck assays. However, given low numbers and wide CIs, a type I error could be a possibility. Also, since different assays were used, can the authors advise whether the increase in antigenemia was similar in the subsamples when using either one of the assays?

Please note that Chagas disease is not found in these countries. As most children tested were very young, they are unlikely to have significant exposure and antibodies to *Schistosomiasis*.

10.7554/eLife.03925.012

Author response

*1) The four populations studied differ in malaria burden, climate and vitamin A use. It is unclear whether some of the differences between the blood film and RDT assessments are due to the omission of Mozambique (one of two countries with relatively high parasite prevalence) from the latter. Further, amidst the range of correcting/confounding variables it is not clear how \'country\' as a geopolitical unit was considered*.

We thank the reviewers for their insightful comment and recognize their concerns. To address the issue of study population differences, we ran a sensitivity analysis using blood film data including and excluding Mozambique from our analysis. This analysis (Author response table 1) showed that when excluding Mozambique data, vitamin A not only remained protective but the magnitude of its protective effect was amplified. In other words, including data from Mozambique in the blood film model, provided a more conservative estimate of vitamin A effects. We have included the more conservative results in our paper. Unfortunately, RDT testing was not conducted among Mozambique subjects making it impossible to conduct similar sensitivity analysis for RDT testing.

Our models did adjust for factors that could explain differences between the four populations (including vitamin A use and climate). This is indicated in the seventh paragraph of the Materials and methods section of the manuscript. Furthermore, to avoid statistical inference errors in our results due to clustering and stratification from the sampling process, we used logistic regression models that accounted for complex survey data structure and defined country and primary sampling unit (∼district) as strata, and household as cluster. We recognize that this was not fully clear in our original paper and have now incorporated this information in the seventh paragraph of the Materials and methods section of the manuscript.

Author response table 1. Adjusted PS-IPW relative risk of malaria, by group of children analyzedType of Vaccine*Adjusted RR (95%CI)Plasmodium spp.* Parasitemia (Microscopic Examination of Blood Film)*Plasmodium falciparum* Antigenemia (Rapid Detection of HRP2) (i.e., excl. Mozambique)All Children (i.e., incl. Mozambique)Children from countries using both film & RDT (i.e., excl. Mozambique)*BCG*1.24 (0.76-2.05)2.71 (1.36-5.39)3.52 (1.66-7.48)*DTP*0.06 (0.01-0.47)0.38 (0.01-10.1)0.06 (0.01-0.38)*Measles*1.01 (0.20-5.19)1.00 (0.18-5.45)0.68 (0.15-3.12)*Polio*0.74 (0.27-2.01)0.60 (0.22-1.62)0.93 (0.37-2.35)*Vitamin A***0.43 (0.36-0.52)0.24 (0.18-0.34)0.22 (0.16-0.29)***Countries included in analysisBurkina Faso, Rwanda, Senegal & MozambiqueBurkina Faso, Rwanda, Senegal*

Abbreviations: PS IPW, Propensity-score inverse probability weighting

*2) Because the populations are not the same for blood film and antigenaemia readings, it is hard to interpret the findings from the two analyses (e.g. for vitamin A, where age--and time--dependent trends with antigen are presented but are difficult to explain biologically, unless they reflect host and environmental/social differences between Burkina Faso, which contributes the overwhelming number of malaria antigen cases, and Mozambique). This makes it difficult to single out the take*--*home message; or have confidence that the antigen findings are generalisable*.

We apologize for the confusion. As previously mentioned, our models was adjusted for factors that could explain population differences. More importantly, our analysis in Author response table 1 shows that when Mozambique data was excluded from the blood film analysis (i.e., populations were identical for blood film and antigenaemia results), the magnitude of protective vitamin A effects increased causing results in both the blood film and antigenemia models to be nearly identical.

Technically speaking, blood films and antigenaemia readings are used to identify two different outcomes. Blood films test for *Plasmodium* spp., while antigenemia is testing for one particular type of *Plasmodium (P.falciparum).* We recognize the confusion caused by using these two terms, and have tried to make the distinction between these tests clearer by re-labeling tables and figure using taxonomic terms for malaria, restructuring [Tables 2 and 3](#tbl2 tbl3){ref-type="table"}, as well as referring to type of *malaria sp*. detection throughout the manuscript. However, it should be noted that due to geography, blood films were likely detecting *P.falciparum*. This would explain the similar results identified between blood film and antigenemia results when excluding Mozambique data from our analysis.

That said, we have chosen to include Mozambique data for blood films in our manuscript since these results provide more conservative estimates of Vitamin A effects. All of this discussion is now included in the fifth paragraph of the Discussion section in the manuscript.

*3) Clearly there is value in capitalising on the cross*--*country comparisons possible from DHS data. But the Methods section could be much clearer on whether children vaccinated were compared with those unvaccinated (and if not, how the groups assessed for protection were selected). Since this is observational rather than trials data, adequate explanation of this design/analysis issue is essential. (High vaccination coverage overall raises the question whether comparing vaccinated against unvaccinated children is valid given possible selection biases*.*)*

We fully agree with the reviewers regarding the value of cross-country comparisons. In fact, during the initial stages of our analysis we had hoped to present country-stratified models, but were unable to do so due to issues with model convergence. A similar problem occurred when including country as a covariate in 'overall' models investigating effect modification. As for the observational nature of the study, we recognized early on that vaccination uptake in itself might introduce a selection bias. To account for this, we used inverse probability weighting by propensity scores. The propensity score was based on known predictors for use of vaccination. We recognize that this may not have been fully clear in our manuscript, and have now included this information under the header "Avoidance of Selection Bias" in the Materials and methods section of the manuscript. Please note that the unweighted models (which did not account for potential vaccination selection bias) provided more conservative estimates, and for this reason are included in the paper.

*4) Quality of National Data: The authors are silent on country*--*level quality control activities for malaria diagnosis, especially on the expertise and methods used by those responsible for blood smear readings*.

We are grateful for the reviewers' comment. Information on both internal and external quality control measures for malaria testing is now included in the fifth paragraph of the Materials and methods section. We have also included quality control measures used for HIV testing in the same section.

*5) Ethical approval: The authors state that "the study was determined exempt from ethics review by Johns Hopkins Bloomberg School of Public Health". It is not appropriate to have such approval from Johns Hopkins only; an understanding of the ethical status of the work in countries where the data were collected is needed. Furthermore, it would be helpful to know how children who tested malaria positive were managed*.

A specific section entitled 'Ethical Considerations' has now been added to the paper, describing detailed information on ethical procedures related to the study. Please note that, aside from ethics review by JHSPH IRB, additional review was conducted during the original DHS survey by the ICF Macro International IRB (all four countries), the National Ethics Committees (three countries), and by the U.S. Centers for Disease Control (one country). Also, if a child tested positive during the survey using malaria RDT, his/her parent/guardian was informed of the results and the child was immediately given treatment according to the current treatment guidelines. This information is now included in the "Ethical Considerations" paragraph in the manuscript.

*6) It is mentioned that 20,948 children presented health cards during the survey interviews. It is stated that 12,028 were tested using thick blood films and 8702 using RDTs, but were the tests on each child limited to either thick film examination or RDT or both? If only one, how was concordance determined; and if both, what was the overlap (and please explain how children were accounted for as either thick film (*[@bib54]*) or RDT (8702) to sum to 20,948)?*

*Note: numbers in the text and* [*Tables 1 and 2*](#tbl1 tbl2){ref-type="table"} *are not all in agreement. Since microscopy is the stated \'gold standard\' it might be clearer if the analysis in* [*Table 1*](#tbl1){ref-type="table"} *included only those children with microscopy results*.

We apologize for the confusion. From 20,948 children who presented health cards during survey interviews, 18,413 were eligible for blood screening from which 12,058 provided capillary blood for malaria testing. [Author response image 1](#fig3){ref-type="fig"} shows that 99.8% of children were tested with blood film, and more than 70% were tested using both blood film and RDT. Less than 0.5% were tested using only RDT. The 12,028 tested using thick films and 8702 tested using RDT's come from the 12,058 subjects providing blood, and not the 20,948 children who presented health cards. We recognize that the flow chart ([Figure 1](#fig1){ref-type="fig"} in our original paper) may not have been clear on this point, and have now included a statement describing the breakdown of diagnostic tests used, in the Results section of the manuscript. Also, as requested by reviewers, [Table 1](#tbl1){ref-type="table"} now only includes children with blood film microscopy results.Author response image 1.Proportion of children tested according to type of diagnostic used.

*7) Please provide information on selection of confounders. And consider: a) HIV status and vertical HIV exposure, as these may influence a child\'s immune response to both vaccination and vitamin A supplementation*;

We appreciate the potential impact of HIV on associations between vitamin A and malaria. Unfortunately, data on children's HIV status was not available. However, 2540 mothers of children participants in Burkina Faso, Rwanda and Senegal were tested by the DHS for HIV status. Using this data, we found less than 1% of mothers tested positive for HIV, suggesting a low potential for vertical transmission in our study population. This information is included in the first paragraph of the Results section. Adjusting for maternal HIV status in models using subjects whose mothers were tested, we found that the association between vitamin A and malaria remained protective (Author response table 2). Still, the low prevalence of maternal HIV in our study population (and hence low statistical power) makes it difficult for us to rule out potential vitamin A\*HIV interactions. We fully recognize the limitations of this indicator and have now included a discussion of these concerns in the Discussion section of the manuscript.

Author response table 2. Adjusted PS-IPW relative risk of malaria, by mother's HIV statusType of Vaccine*Adjusted RR (95%CI)Plasmodium spp.* Parasitemia (Microscopic Examination of Blood Film)*Plasmodium falciparum* Antigenemia (Rapid Detection of HRP2)Not adjusting for mother's HIV statusAdjusting for mother's HIV statusNot adjusting for mother's HIV statusAdjusting for mother's HIV status*BCG*2.71 (1.36-5.39)2.20 (0.68-7.10)3.23 (1.58-6.61)2.17 (0.66-7.10)*DTP*0.38 (0.01-10.1)0.93 (0.23-3.82)0.07 (0.01-0.48)1.34 (0.51-3.54)*Measles*1.00 (0.18-5.45)0.66 (0.30-1.45)0.73 (0.15-3.61)0.86 (0.43-1.72)*Polio*0.60 (0.22-1.62)1.75 (0.56-5.49)0.81 (0.28-2.31)3.27 (1.17-9.15)*Vitamin A*0.24 (0.18-0.34)0.09 (0.04-0.19)0.23 (0.17-0.31)0.13 (0.06-0.27)

*b) Number of doses of each of the immunizations or vitamin A supplements received (it is likely that older children had more immunizations and A supplements than younger)*. *Were immunization schedules and supplementation programmes similar in the four countries?*

Our study models controlled for age both through the use of propensity scores and in the actual model. As for immunization and vitamin A schedules, Author response table 3 shows that they were fairly similar across different countries. The main distribution mechanism was also similar for vitamin A. We have included this information in the first paragraph of the Results section of the revised manuscript.

Author response table 3. Overview of Immunization Schedules for each country^1^Type of Vaccination/SupplementationCountryBurkina FasoMozambiqueRwandaSenegal*BCG*BirthBirthBirthBirth*DTP*8,12,16 weeks\* (DTP)6,10,14 weeks (DTPHep)6,10,14 weeks (DTPHibHep)6,10,14 weeks (DTPHibHep)*Measles*9 months9 months9 months9 months*Polio*Birth,8,12,16 weeks\*6,10,14 weeksBirth, 6,10,14 weeksBirth, 6,10,14 weeks*Vitamin A*Every 6 months from ages 6-59 months *Main Distribution Mechanism*:Integrated Child Health campaignEvery 6 months from ages 6-59 months *Main Distribution Mechanism*:Integrated Child Health campaignEvery 6 months from ages 6-59 months *Main Distribution Mechanism*:Integrated Child Health campaignEvery 6 months from ages 6-59 months *Main Distribution Mechanism*:Integrated Child Health campaign

\*Guidelines report immunization schedule in months (2,3,4 months). Converted into weeks for this table.

^1^Adapted from: Unicef and WHO. Immunization Summary: The 2007 Edition. (published February 2007), Vaccination Information Management System: [www.vimsdata.org](http://www.vimsdata.org/) (Last accessed September 19, 2014) and personal communication with E. Alden (UNICEF) on December 8, 2014.

*8) Third paragraph in the Results section: the authors indicate that vitamin A was more protective the greater the time from the last dose. The last panel of* [*Figure 2*B](#fig2){ref-type="fig"} *does not seem to show this, nor does the statement tally with the first paragraph of the Discussion*.

We apologize for the confusion. The increasingly protective effect occurs with malaria antigenemia but not malaria parasitemia. To avoid any confusion, this phrase has now been removed from the Discussion.

*9) Fourth paragraph in the Discussion section: the authors suggest that the increase in antigenemia associated with BCG vaccination might be due to false positivity from other parasitic infections; also that false--positivity has been reported in Paracheck assays. However, given low numbers and wide CIs, a type I error could be a possibility. Also, since different assays were used*, *can the authors advise whether the increase in antigenemia was similar in the subsamples when using either one of the assays?*

*Please note that Chagas disease is not found in these countries. As most children tested were very young, they are unlikely to have significant exposure and antibodies to* Schistosomiasis.

We thank the reviewers' for their observations. We have now included an explicit statement in the fourth paragraph of the Discussion section that Chagas is not endemic in the countries we studied. As for *Schistosomiasis*, there is growing evidence to suggest it may be an overlooked endemic disease among infants and young children in Africa. We have included a statement and reference to this material in the same section of the text. Finally, in terms of examining increases in antigenemia stratified by type of RDT, regrettably, the small sample size particularly in the BCG-negative, malaria-positive cells (2x2 table) led to problems in model convergence when stratifying results by diagnostic used.

[^1]: *P*ƒ-HRP-2 testing not conducted as part of DHS survey protocol for Mozambique.

[^2]: Information on insecticide spraying not collected as part of survey.

[^3]: HRP-2: histidine rich protein-2; RR: relative risk; CI: confidence interval; IPW: inverse probability weighted model.

[^4]: Tested in four countries: Burkina Faso, Mozambique, Rwanda and Senegal.

[^5]: Tested in three countries: Burkina Faso, Rwanda and Senegal.

[^6]: Adjusted for the following factors: age, gender, wealth index score, mother\'s highest level of education, malaria treatment during previous week, ownership of bed net, proportion of household members under 5 years using bed net during previous night, indoor household insecticide spraying, mother\'s access to antenatal care during last pregnancy, mother\'s knowledge regarding vertical HIV transmission, malaria transmission season, and type of community setting (urban vs rural).

[^7]: Inverse probability weighting (IPW) based on propensity score model with following factors: age, gender, low birth weight, presence of radio or television, urban versus rural setting, breastfeeding status, wealth index score, mother\'s age, mother\'s highest education level, antenatal care during last pregnancy, and mother\'s tetanus status during last pregnancy.

[^8]: HRP-2: histidine rich protein 2; RR: relative risk; CI: confidence interval; na: not applicable: ref: reference category; HbS: hemoglobin S; G6PD: glucose 6-phosphate dehydrogenase deficiency.

[^9]: Tested in four countries: Burkina Faso, Mozambique, Rwanda and Senegal.

[^10]: Tested in three countries: Burkina Faso, Rwanda and Senegal.

[^11]: Adjusted for the following factors: age, gender, wealth index score, mother\'s highest level of education, malaria treatment during previous week, ownership of bed net, proportion of household members under 5 years using bed net during previous night, indoor household insecticide spraying, mother\'s access to antenatal care during last pregnancy, mother\'s knowledge regarding vertical HIV transmission, malaria transmission season, and type of community setting (urban vs rural).

[^12]: Geographical waypoints were not recorded for 40 communities. Subjects from these PSUs were excluded from analysis.

[^13]: Covariate treated as continuous term when testing for effect modification in the model.
